A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of the FDA.
5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis
A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of the FDA.